Major Shareholder Van Herk Investments' Stake Diluted to 10.9% Post-Offering
PRQR sits 44% above its 52-week low of $1.33.
Summary
Van Herk Investments' stake in ProQR Therapeutics has been diluted to 10.9% following the company's recent $59.2 million offering, without any share sales by the investor.
Key Events · Ownership and Investor Activity · PRQR
-
Shareholder Stake Reduced
Van Herk Investments' ownership stake decreased from 14.6% to 10.9% of outstanding shares.
-
Passive Dilution
The change in percentage is solely due to the company's recent $59.2 million capital raise, which increased the total number of outstanding shares. Van Herk Investments did not sell any shares.
-
Follows Prior Activism
This update follows a previous Schedule 13D/A where Van Herk Investments, a significant shareholder, had threatened legal action against the company.
Analysis · PRQR · Life Sciences
This Schedule 13D/A updates Van Herk Investments' ownership stake in ProQR Therapeutics to 10.9% from 14.6%. The reduction is a direct result of the company's recent $59.2 million capital raise, which increased the total outstanding shares. Van Herk Investments did not sell any shares; their percentage ownership decreased due to dilution. This update is significant as Van Herk Investments previously threatened legal action against the company.
At the time of this filing, PRQR was trading at $1.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $196M. The 52-week trading range was $1.33 to $3.10. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.